Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002881 · ClinicalTrials.gov registry record · Phase 3
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002881: Completed Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
NCT00002881 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002881, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Hormone therapy may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to evaluate the effectiveness of treatment with flutamide and suramin with or without hydrocortisone in men who have metastatic or recurrent prostate cancer.
Interventions
- DRUG leuprolide acetate
- DRUG goserelin acetate
- DRUG flutamide
- DRUG therapeutic hydrocortisone
- DRUG suramin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-10 |
| Phase | Phase 3 |
What the finished NCT00002881 record still lists
NCT00002881 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which leuprolide acetate is the first listed.
NCT00002881 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002881 about?
NCT00002881 is a clinical study titled "Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer". RATIONALE: Hormone therapy may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to evaluate the effectiveness of treatment with flutamide and suramin with or without hydrocortisone in men who have metastatic or recurrent prostate cancer.
What is the current status of trial NCT00002881?
This trial is currently completed. It is a Phase 3 study. The study started on 1996-10.
What interventions are being tested in trial NCT00002881?
The interventions under investigation include: leuprolide acetate (DRUG), goserelin acetate (DRUG), flutamide (DRUG), therapeutic hydrocortisone (DRUG), suramin (DRUG).
Who is sponsoring clinical trial NCT00002881?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia